^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Oncaspar lyophilized (pegaspargase lyophilized)

    i
    Other names: S95014 lyophilized, lyophilized S95014
    Associations

    News

    Trials
    Company:
    Servier
    Drug class:
    Asparagine depleter
    Related drugs:
    Associations

    News

    Trials
    over1year
    COMPARISON OF THE PHARMACOKINETICS OF THE LIQUID AND THE LYOPHILIZED FORMULATIONS OF PEGASPARGASE IN THE TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) (EHA 2023)
    In summary, the results support the conclusion that the PK exposure of pegaspargase after IV administration at the dose of 2,500 U/m 2 does not depend on the drug formulation. Pharmacokinetics and safety results of this study are consistent with previously observed pegaspargase data. Pediatric, Pharmacokinetic, Acute lymphoblastic leukemia
    Clinical • PK/PD data
    |
    Oncaspar liquid (pegaspargase) • Oncaspar lyophilized (pegaspargase lyophilized)